LITTLE FALLS, N.J., Nov. 13 CANTEL MEDICAL CORP. (NYSE: CMN) announced today that it will be added to the S&P SmallCap 600 Index on a date to be announced by Standard & Poor's. This index covers approximately 3% of the domestic equities market and is designed to be an efficient portfolio of companies that meet specific inclusion criteria to ensure that they are investable and financially viable.
Cantel's President and CEO, Andrew Krakauer stated, "We are pleased that the S&P Index Committee has selected us for inclusion in the S&P SmallCap 600. This listing recognizes our market capitalization, financial viability, public float and strong liquidity and provides us with additional visibility as a market leader in the healthcare industry."
Criteria for addition to the S&P SmallCap 600 Index includes a market capitalization in the range of $200 million to $1 billion, four consecutive quarters of positive GAAP Net Income, a public float of at least 50% and a ratio of annual dollar value traded to market capitalization of 0.30 or greater.
About Cantel Medical Corp.
Cantel Medical Corp. (NYSE: CMN) is a leading provider of infection prevention and control products in the healthcare market. Our products include specialized medical device reprocessing systems for renal dialysis and endoscopy, dialysate concentrates and other dialysis supplies, disposable infection prevention and control products primarily for the dental industry, water purification equipment, sterilants, disinfectants and cleaners, hollow fiber membrane filtration and separation products for medical and non-medical applications, and specialty packaging for infectious and biological specimens. We also provide technical maintenance for our products and offer compliance training services for the transport of infectious and biological specimens. For more information please visit http://www.cantelmedical.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including, without limitation, the risks detailed in Cantel's filings and reports with the Securities and Exchange Commission. Such forward-looking statements are only predictions, and actual events or results may differ materially from those projected or anticipated.
SOURCE Cantel Medical Corp.